Celularity Inc. (NASDAQ:CELU) Sees Large Increase in Short Interest

Celularity Inc. (NASDAQ:CELU - Get Free Report) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 743,700 shares, a growth of 9.3% from the October 15th total of 680,500 shares. Currently, 6.9% of the company's shares are short sold. Based on an average trading volume of 876,800 shares, the days-to-cover ratio is presently 0.8 days.

Celularity Price Performance

CELU traded up $0.21 on Friday, hitting $2.46. 4,624,191 shares of the company were exchanged, compared to its average volume of 2,911,333. The firm has a fifty day simple moving average of $2.55 and a two-hundred day simple moving average of $2.88. Celularity has a 12 month low of $1.30 and a 12 month high of $7.97.

Celularity (NASDAQ:CELU - Get Free Report) last issued its earnings results on Wednesday, October 16th. The company reported ($1.03) earnings per share (EPS) for the quarter. Celularity had a negative return on equity of 92.48% and a negative net margin of 264.30%. The firm had revenue of $14.68 million during the quarter.

Institutional Trading of Celularity

A hedge fund recently bought a new stake in Celularity stock. Keynote Financial Services LLC purchased a new stake in shares of Celularity Inc. (NASDAQ:CELU - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,566 shares of the company's stock, valued at approximately $81,000. Keynote Financial Services LLC owned about 0.08% of Celularity at the end of the most recent reporting period. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.